Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1977 Apr;4(2):135–140. doi: 10.1111/j.1365-2125.1977.tb00684.x

Comparative beta-adrenoceptor blocking effects and pharmacokinetics of penbutolol and propranolol in man.

J F Giudicelli, C Richer, M Chauvin, N Idrissi, A Berdeaux
PMCID: PMC1429010  PMID: 16632

Abstract

1 The beta-adrenoceptor blocking effects of penbutolol were compared with those of propranolol and a placebo in a double-blind trial involving six healthy volunteers. 2 Heart rate (HR), systolic blood pressure (SBP) and peak expiratory flow rate (PEFR) were measured at rest and during vigorous exercise before and at intervals up to 7 h after oral administration of the drugs. In addition, plasma renin activity (PRA) at rest and plasma levels of penbutolol and propranolol were determined. 3 Penbutolol proved to be a non-cardioselective beta-adrenoceptor blocking drug, antagonizing exercise-induced tachycardia, reducing exercise-induced increase in PEFR and decreasing PRA. The beta-adrenolytic potency of penbutolol was shown to be four-fold that of propranolol but the duration of its effect was similar. 4 The peak plasma level of penbutolol was reached 1 h after administration and its half-life was 4.5 h. 5 Comparison of plasma levels and biological activity of penbutolol revealed that after oral administration this drug is transformed into an active metabolite in man.

Full text

PDF
135

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boissier J. R., Coutte R., Advenier C., Giudicelli J. F. Activité beta-adrénolytique et effets hémodynamiques du penbutolol. Therapie. 1973 Nov-Dec;28(6):1251–1265. [PubMed] [Google Scholar]
  2. Cuthbert M. F., Collins R. F. Plasma levels and beta-adrenoceptor blockade with acebutolol, practolol and propranolol in man. Br J Clin Pharmacol. 1975 Feb;2(1):49–55. doi: 10.1111/j.1365-2125.1975.tb00471.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fitzgerald J. D., Scales B. Effect of a new adrenergic beta-blocking agent (ICI 50,172) on heart rate in relation to its blood levels. Int Z Klin Pharmakol Ther Toxikol. 1968;1(6):467–474. [PubMed] [Google Scholar]
  4. Gugler R., Höbel W., Bodem G., Dengler H. J. The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Clin Pharmacol Ther. 1975 Feb;17(2):127–133. doi: 10.1002/cpt1975172127. [DOI] [PubMed] [Google Scholar]
  5. Hansson B. G., Hökfelt B. Long term treatment of moderate hypertension with penbutolol (Hoe 893d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise. Eur J Clin Pharmacol. 1975 Oct 10;9(1):9–19. doi: 10.1007/BF00613424. [DOI] [PubMed] [Google Scholar]
  6. Hicks D. C., Arbab A. G., Turner P., Hills M. A comparison of intravenous pindolol and propranolol in normal man. J Clin Pharmacol New Drugs. 1972 May-Jun;12(5):212–216. doi: 10.1002/j.1552-4604.1972.tb00164.x. [DOI] [PubMed] [Google Scholar]
  7. Härtfelder G., Lessenich H., Schmitt K. Penbutolol (Hoe 893 d), ein neues, stark wirksames -sympatholytikum mit langer Wirkungsdauer. Arzneimittelforschung. 1972 May;22(5):930–932. [PubMed] [Google Scholar]
  8. Hökfelt B., Hedeland H., Hansson B. G. The effect of clonidine and penbutolol, respectively on catecholamines in blood and urine, plasma renin activity and urinary aldosterone in hypertensive patients. Arch Int Pharmacodyn Ther. 1975 Feb;213(2):307–321. [PubMed] [Google Scholar]
  9. Marlin G. E., Kumana C. R., Kaye C. M., Smith D. M., Turner P. An investigation into the cardiac and pulmonary beta-adrenoceptor blocking activity of ICI 66,082 in man. Br J Clin Pharmacol. 1975 Apr;2(2):151–157. doi: 10.1111/j.1365-2125.1975.tb01570.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Morgan T. O., Roberts R., Carney S. L., Louis W. J., Doyle A. E. Beta-adrenergic receptor blocking drugs, hypertension and plasma renin. Br J Clin Pharmacol. 1975 Apr;2(2):159–164. doi: 10.1111/j.1365-2125.1975.tb01571.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. ROBINSON S., PEARCY M., BRUECKMAN F. R., NICHOLAS J. R., MILLER D. I. Effects of atropine on heart rate and oxygen intake in working man. J Appl Physiol. 1953 Mar;5(9):508–512. doi: 10.1152/jappl.1953.5.9.508. [DOI] [PubMed] [Google Scholar]
  12. Shand D. G., Nuckolls E. M., Oates J. A. Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):112–120. doi: 10.1002/cpt1970111112. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES